News – Page 877 – Endpoints News

Roche's checkpoint player Tecentriq flops in another bladder cancer subset

6 years ago

2019 a 'transformative year' for pharma M&A. Is that a good thing?

6 years ago

Diabetes-focused Poxel names Eli Lilly vet David Moller as CSO; Acceleron's CBO hops ship to lead startup

6 years ago

British Heart Foundation unveils shortlist for £30M research award; Onconova scraps China partnership

6 years ago

Merck KGaA spinout gets first funding to bring dual-acting cancer molecules into the clinic

6 years ago

Eli Lilly’s $1.6B cancer drug failed to spark even the slightest positive gain for patients in its 1st PhIII

6 years ago

Amgen augments Asia foothold by taking over Astellas joint venture in Japan

6 years ago

PureTech bags $200M from sale of Karuna shares — still sizzling from promising schizophrenia data

6 years ago

The FDA has devalued the gold standard on R&D. And that threatens everyone in drug development

6 years ago

Roche cracks China's ADC market open as Kadcyla scores its first breast cancer OK in the country

6 years ago

Pascal Soriot and AstraZeneca commit to zero-carbon by 2025, carbon-neutral by 2030. Where's the rest of Pharma?

6 years ago

New players are jumping into the scramble to develop a vaccine as pandemic panic spreads fast

6 years ago

Fresh trial data fortify position of Roche's oral therapy in spinal muscular atrophy battleground

6 years ago

Wuhan virus outbreak triggers inevitable small-biotech rally

6 years ago

Brexit fears, Woodford woes overshadowed UK biotech and cut 2019 financing by almost half

6 years ago

Blueprint Medicines potentially delays Ayvakit decision; Control beats treatment in mesothelioma trial

6 years ago

Transitional leaders take charge as FDA begins PhIII of OND reorganization

6 years ago

Chicago investor devises £250M deal as real estate grows with UK's biotech sector

6 years ago

Ionis, Akcea boosted by a positive PhII for their Novartis castoff cardio drug — and they plan to push ahead into ...

6 years ago

NICE stays sour on AstraZeneca's Tagrisso

6 years ago

FDA’s golodirsen CRL: Sarepta’s Duchenne drugs are dangerous to patients, offering only a small benefit. And ...

6 years ago

French-Belgian biotech banks €20M to break ground in blood-splattered field of therapeutic cancer vaccines

6 years ago

Eli Lilly reserves $470M for new manufacturing plant — and North Carolina is more than pleased

6 years ago

FDA hands off its latest whirlwind drug OK as Horizon hustles would-be blockbuster to the market

6 years ago

First page Previous page 874 875 876877878 879 880 Next page Last page